Given the approval of TKI/Src inhibitors in the clinic,56 as well as the ongoing evaluation of MCL-1 antagonists in leukemia and multiple other malignancies,18 the Src/MCL-1 strategy may warrant attention in AML and potentially other neoplastic disorders. This evidence concerns the gene SRC and leukemia.